BMS 986463
Alternative Names: BMS-986463Latest Information Update: 20 Aug 2024
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (unspecified route) (NCT06476808)
- 05 Jul 2024 Bristol Myers Squibb plans a phase I/Ib trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in the US and Canada (Unspecified) (NCT06476808).
- 05 Jul 2024 Preclinical trials in Solid tumours in USA (unspecified route) prior to July 2024.